Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis

Oncology Letters
Alessandro FedericoFerdinando DE Vita

Abstract

Sorafenib confers a survival benefit for patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh (CP) A liver cirrhosis. At present, limited data exists with regard to the safety and efficacy of sorafenib in treating CP-B HCC patients. The present study describes the use of sorafenib in patients with HCC and CP-A or -B cirrhosis. Clinical data was obtained from patients with HCC who were treated with sorafenib at the Department of Clinical and Experimental Medicine, Second University of Naples (Naples, Italy) and were analyzed retrospectively in terms of tumor response, tolerance and survival. The treatment outcomes were analyzed according to the respective CP status. The adverse events (AEs) were graded using the Common Terminology Criteria for Adverse Events, version 3.0, and the tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors, version 1.2. In total, 26 patients received sorafenib at 400 mg twice daily. The median age was 69 years (range, 58-81 years) and the ratio of males to females was 18:8. Overall, 15 patients were infected with the hepatitis C virus (HCV), eight with HBV and three were co-infected with HCV/HBV. In total, 20 (77%) patients presented with an underlyin...Continue Reading

References

Oct 13, 1999·Seminars in Liver Disease·J M LlovetJ Bruix
Oct 27, 2005·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Jordi BruixUNKNOWN Practice Guidelines Committee, American Association for the Study of Liver Diseases
Feb 14, 2007·Seminars in Liver Disease·Augusto VillanuevaJosep M Llovet
Jun 16, 2007·Gastroenterology·Hashem B El-Serag, K Lenhard Rudolph
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Jan 15, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Puneeta Tandon, Guadalupe Garcia-Tsao
Jan 16, 2009·The Oncologist·Matthias PinterMarkus Peck-Radosavljevic
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonius A MillerMark J Ratain
Nov 27, 2009·European Journal of Gastroenterology & Hepatology·Markus Peck-RadosavljevicLuigi Bolondi
Mar 30, 2011·Cancer Chemotherapy and Pharmacology·Jeong Eun KimYoon-Koo Kang
Sep 8, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Massimo IavaroneUNKNOWN SOFIA (SOraFenib Italian Assessment) study group
Oct 1, 2011·Alimentary Pharmacology & Therapeutics·A HollebecqueP Mathurin
May 10, 2012·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Shuichi KanekoYukinori Imai
Aug 10, 2012·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jon ZugazagoitiaEduardo Díaz-Rubio

❮ Previous
Next ❯

Citations

Nov 29, 2015·Asian Pacific Journal of Tropical Medicine·Li-Yan WangYong Liu
Apr 1, 2016·Hepatic Oncology·Francesco TovoliLuigi Bolondi
Jun 28, 2018·Investigational New Drugs·Cassia Regina Guedes LealSérgio Setubal
Jul 3, 2015·Oncology Letters·Xianli ChenXingnan Pan

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.